Literature DB >> 7593249

Heparin binding, internalization, and metabolism in vascular smooth muscle cells: II. Degradation and secretion in sensitive and resistant cells.

D Letourneur1, B L Caleb, J J Castellot.   

Abstract

Smooth muscle cell (SMC) proliferation plays a critical role in several pathological states, including atherosclerosis and hypertension. Heparin suppresses SMC proliferation in vivo and in culture, but the mechanism of action is still poorly understood. In an accompanying article in this issue (Letourneur et al. [1995] J. Cell Physiol., 165:676-686), we observed that heparin binding was up-regulated in heparin-sensitive SMC but was rapidly down-regulated in heparin-resistant SMC continuously exposed to heparin. In this communication, we examine the degradation and secretion of internalized heparin in sensitive and resistant SMC, using gel filtration chromatography to analyze heparin degradation products. Pulse-chase experiments using radiolabeled heparin indicate that sensitive and resistant SMC secrete heparin during the first few hours after exposure. Experiments in which cells are continuously exposed to heparin indicate that degradation and secretion occur in both sensitive and resistant SMC for approximately 5-8 hr. After that time, however, binding and internalization in resistant SMC rapidly decrease and degradation and secretion stop. In contrast, heparin binding and uptake continue in sensitive SMC; degradation and secretion also continue. Chloroquine prevents degradation in both sensitive and resistant SMC, suggesting that catabolism occurs in the lysosomal compartment. The results presented in this and the accompanying article (Letourneur et al. [1995] J. Cell. Physiol., 165:676-686) suggest that heparin acts to upregulate its receptors, and that increased binding of heparin is required for the antiproliferative response. Degradation and secretion kinetics parallel the internalization kinetics and appear to be strongly linked to the binding process.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593249     DOI: 10.1002/jcp.1041650328

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  5 in total

1.  Heparin inhibits phosphorylation and autonomous activity of Ca(2+)/calmodulin-dependent protein kinase II in vascular smooth muscle cells.

Authors:  Ketu Mishra-Gorur; Harold A Singer; John J Castellot
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Nitric oxide degradation of heparin and heparan sulphate.

Authors:  R E Vilar; D Ghael; M Li; D D Bhagat; L M Arrigo; M K Cowman; H S Dweck; L Rosenfeld
Journal:  Biochem J       Date:  1997-06-01       Impact factor: 3.857

3.  Characterization of [3H]-heparin binding in human vascular smooth muscle cells and its relationship to the inhibition of DNA synthesis.

Authors:  M K Patel; J S Refson; M Schachter; A D Hughes
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

4.  Chondroitin sulphate inhibits connective tissue mast cells.

Authors:  T C Theoharides; P Patra; W Boucher; R Letourneau; D Kempuraj; G Chiang; S Jeudy; L Hesse; A Athanasiou
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

5.  Low-molecular-weight heparin and unfractionated heparin decrease Th-1, 2, and 17 expressions.

Authors:  Jing-Ning Huang; Ming-Chin Tsai; Shun-Lung Fang; Margaret Dah-Tsyr Chang; Yu-Rou Wu; Jaw-Ji Tsai; Lin-Shien Fu; Heng-Kuei Lin; Yi-Jun Chen; Tsai-Wei Li
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.